Recent Highlights in Targeted Protein Degradation

In this Drug Hunter Flash Talk, we discuss scientific highlights from small molecules that induce the degradation of their targets of interest, with a focus on molecules that have recently demonstrated important proofs-of-concept in the clinic. The talk covers: -Theoretical advantages of targeted protein degradation over traditional small molecules -Recent highlights throughout the industry illustrating these advantages -Areas to watch in targeted protein degradation on the horizon -Some of the highlights mentioned in the talk include: -9:00: Ten ways degraders can differentiate in theory -14:47: Agnostic to ligand mode of action: AR degraders -16:18: AR degraders and ER degraders from Arvinas (bavdegalutamide/ARV-110, ARV-766, and ARV-471) -18:58: MDM2 degraders from Kymera (e.g. KT-253) -20:30: BRAF and allosteric EGFR degraders from C4 and Roche (e.g. CFT1946, CFT8919) -21:43: IRAK4 degraders from Kymera (e.g. KT-474) -22:54: BRD9 and BRM/BRG1 degraders from C4 Therapeutics and Prelude Therapeutics -24:41: BTK degraders from Nurix (e.g. NX-2127, NX-5948) -26:24: IV STAT3 degraders from Kymera Therapeutics (e.g. KT-333 and KT-003) -27:45: RIPK2 degraders from GSK and PCSK9 degraders from Merck -28:55: EGFR L858R degrader from Roche and C4 (e.g. compound 144) -30:32: PCSK9 degrader from Merck (e.g. compound 16) -32:17: A tissue-selective Bcl-XL degrader from Dialectic Therapeutics (e.g. DT2216) -33:31: BRAF degrader from C4 Therapeutics (e.g. CFT1946) -35:00: Brain-penetrant degraders -36:20: A cyclin D1 degrader from Mt. Sinai (e.g. MS28) 37:38:Ten ways degraders can differentiate in theory -38:22: Areas to watch in targeted protein degradation on the horizon: Presented by: Dennis Hu, CEO & Editor-in-Chief, Drug Hunter with co-host Pierre Morieux, Chemistry Product Marketing Manager, Revvity Signals. Presented on June 28, 2023, as part of the Drug Hunter Flash Talk series. Sign up for future sessions here: https://lu.ma/w1q906iz